Alzheimer's amyloid precursor protein (APP) 1 is an integral membrane protein with a receptor-like structure (1). A principal component of parenchymal amyloid deposits in Alzheimer's disease (AD) is ␤-amyloid (A␤) (2-4), which is derived from APP by proteolytic cleavage (1, 5-11). A␤ is thought to be generated through an intracellular protein secretory pathway of APP (for a review, see Ref. 12). The short APP cytoplasmic domain consisting of 47 amino acid residues is thought to be responsible for determination of APP metabolism (13-15) and possible signal transduction from a putative extracellular ligand that has yet to be identified (for a review, see Ref. 16). Because APP is a candidate pathogenic factor of AD, elucidation of the physiological function of APP as well as the determination of the metabolic mechanism of A␤ production should increase our understanding of the pathogenesis of AD. Using a yeast two-hybrid system, we isolated cDNA of proteins that interact with the cytoplasmic domain of APP (APP COOH ) in order to elucidate the molecular mechanisms of APP metabolism and function of APP. Previous efforts to identify and isolate proteins associating with APP COOH , utilizing the yeast two-hybrid system, have resulted in the isolation of proteins carrying phosphotyrosine binding/phosphotyrosine interaction (PI) domains such as Fe65 (17), 19) , and X11 (20). The X11 gene, which is located on chromosome 9, was originally isolated as a gene candidate for Friedreich ataxia (21) and its partial cDNA was identified as a clone encoding a protein that associates with APP COOH (22) . The PI domain of X11 interacts with the YENPTY motif of APP COOH (20) . In the present study, we isolated a complete cDNA encoding an X11-like protein (X11L) from a human adult brain cDNA library, utilizing the yeast two-hybrid system and APP COOH as a bait. A partial short cDNA encoding approximately 190 amino acids in the PI domain of X11L has already been isolated using a similar procedure (22). However, detailed characterization of X11L binding to APP and identification of the role X11L plays in the physiological function of APP have not been performed. We found that human X11L requires a sequence containing the NPXY motif of APP COOH for APP binding and that association of the PI domain with APP was suppressed by a deletion of a amino-terminal domain fused to the PI domain (PI ϩ C construct) but enhanced by a deletion of a carboxyl-terminal domain fused to the PI domain (N ϩ PI construct). Co-transfection of full-length human X11L into cells that express stably transfected human APP695 cDNA resulted in decreased secretion of A␤40 but not A␤42. However, co-transfection into cells of the cDNA lacking the carboxyl-terminal domain (N ϩ PI construct) or a cDNA encoding only the PI domain (PI construct), whose protein products preserve the ability to bind to APP COOH , did not present the ability to modulate A␤ production. The present results suggest that the amino-terminal region of the PI domain is needed to regulate binding affinity to
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APP COOH and that the carboxyl-terminal region of the PI domain is essential for modulation of APP metabolism. Furthermore, Northern blot and Western blot analyses demonstrated strong specific expression of the X11L gene in brain tissues. Together with the present results, this suggests that X11L may play an important role in the physiological function and metabolism of APP in neuronal tissues.
EXPERIMENTAL PROCEDURES
Yeast Two-hybrid System, cDNA Cloning of Human and Mouse X11-like Protein, and Plasmid Construction-The yeast two-hybrid system, MATCH MAKER Two-Hybrid System, was purchased from CLON-TECH Laboratories, Inc. (Palo Alto, CA). The cDNA encoding APP COOH , located between amino acids 649 and 695 (numbering as for the APP695 isoform), was amplified by PCR using the APP695 cDNA present in pcDNA3 (23) . The PCR product, which was produced by additional EcoRI sequence in 5Ј upstream and BamHI sequence in 3Ј downstream, was digested with EcoRI plus BamHI, and the restriction fragment was inserted into pGBT9 at identical restriction sites in-frame with the GAL4 encoding sequence present on this vector. The resulting pGBT9APP COOH "bait" plasmid was used to isolate the cDNA of the APP-binding protein from a human adult brain cDNA library cloned into the vector pGAD424, which contains the GAL4 transactivation domain. Both plasmids were co-transfected into the yeast HF7c strain (MATa, 112, , LYS::GAL1-HIS3, URA:: (GAL4 17-mer) 3 -CYC1-LacZ) (24) using the lithium acetate/heat shock procedure according to the manufacturer's product protocol (catalog no. PT1265-1, CLON-TECH Laboratories). Because the HF7c strain harbors the reporter genes lacZ and HIS3, co-transformants were streaked first on selection medium lacking tryptophan, leucine, and histidine to assay for activation of the HIS3 reporter gene. Positive colonies were then picked and assayed for activation of the lacZ reporter gene as evidenced by their blue color. Plasmids from colonies positive for both reporter genes were rescued into Escherichia coli HB101. The rescued plasmids were reassayed for their binding activity to the cytoplasmic domain of APP by transfection into HF7c harboring the "bait" plasmid. Finally, the nucleotide sequences of the positive clones were determined by the dideoxy terminator cycle sequencing using a Prism 377 DNA Sequencer (Perkin-Elmer), and the homology of the deduced amino acid sequence to existing sequences in the data bases was investigated using the BLAST program.
The 5Ј nucleotide sequence of one cDNA, pGAD424#104, isolated by the yeast two-hybrid system encoded the 624-amino acid sequence of human X11L protein. The deleted amino-terminal region consisting of 125 amino acids was determined by the RACE procedure (Life Technologies, Inc.; 5Ј-RACE system version 2) using human whole brain poly(A) ϩ RNA (CLONTECH Laboratories; catalog no. 6516-1) and primers corresponding to the amino acid sequence indicated by the underline in Fig. 1a . The 5Ј-RACE product was inserted into the pCRII TA cloning vector (Invitrogen), pCRII5ЈhX11L. Mouse X11L (previously referred to as mouse X11 in Refs. 22 and 25) cDNA was isolated by reverse transcription-PCR using two sets of primers. The primer sequence was designed from the known partial nucleotide sequence of mouse X11 (DDBJ/EMBL/GenBank TM accession no. L34676). A combination of primers consisting of primer 1 corresponding to nucleotide positions 5-22 (forward, numbering for L34676) and primer 2 corresponding to nucleotide positions 839 -856 (reverse, numbering for L34676) and another combination of primers consisting of primer 3 corresponding to nucleotide positions 839 -856 (forward, numbering for L34676) and primer 4 corresponding to nucleotide positions 2041-2059 (reverse, numbering as for L34676) were used to amplify whole mouse brain poly(A) ϩ RNA using Pwo DNA polymerase (Boehringer Mannheim). The resulting 0.8-kb (primers 1 and 2) and 1.2-kb PCR (primers 3 and 4) products were cloned separately into pCRII to give, respectively, pCRIImX11L-1, which contains the nucleotide sequence encoding the amino acid sequence between positions 70 and 353 (numbering as for Fig. 1a) , and pCRIImX11L-2, which contains the nucleotide sequence encoding the amino acid sequence between positions 348 and 748 (numbering as for Fig. 1a) . The 5Ј unknown nucleotide sequence was also determined by the RACE procedure using the mouse brain poly(A) ϩ RNA and primers corresponding to the amino acid sequences indicated by underlines in Fig. 1 . The 5Ј-RACE product, corresponding to amino acid positions 1-69 (numbering for Fig. 1a) , was inserted into pCRII to give pCRIITA5ЈmX11L.
The insert from pGAD424#104 and the cDNA encoding the 5Ј region of human X11L, pcRIITA5ЈhX11L, were ligated. The resulting entire cDNA encoding the entire human X11L protein was inserted into pcDNA3 (Invitogen, Carlsbad, CA) with (pcDNA3-FLAG-hX11L) or without (pcDNA3-hX11L) the addition of a synthetic linker encoding the FLAG epitope on the carboxyl-terminal side of the inserts. The amino acid sequence of human X11L, consisting of 749 amino acids, and that of mouse X11L, consisting of 748 amino acids, were deduced from the nucleotide sequence of each cDNA and are indicated in Fig. 1 .
The cDNA clones encoding the partial amino-terminal domain (pGAD424#6; amino acids 121-367), PI domain (pGAD424#PI; 368 -555), carboxyl-terminal domain (pGAD424#7; 556 -749), amino-terminal domain attached to the PI domain (pGAD424#1; 121-555), PI domain attached with the carboxyl-terminal domain (pGAD424#4; 368 -749), and almost the entire sequence of human X11L (pGAD424#104; 121-749) were subcloned into pGAD424 harboring the GAL4 transactivation domain. These plasmids were used for the APP binding assay in co-transfections with pGBT9APP COOH using the yeast twohybrid system. The cDNA encoding APP COOH was truncated internally at regions 681-690 (pGBT9APP695⌬681-690) and 669 -680 (pGBT9APP695⌬669 -680). The cDNA encoding the cytoplasmic domain of amyloid precursor-like protein 2 (APLP2) was cloned from an adult human brain cDNA library by the reverse yeast two-hybrid system with the "bait vector," pGBT9#104, and the cDNA encoding the cytoplasmic domain of human amyloid precursor-like protein 1 (APLP1) was cloned by reverse transcription-PCR using human brain poly(A)
ϩ RNA and primers with nucleotide sequences corresponding to positions 605-611 (forward) and 644 -650 (reverse) (numbering as for the human APLP1 genome sequence, DDBJ/EMBL/GenBank TM accession no. AD000864). These cDNAs encoding 53 and 47 amino acid residues of the cytoplasmic domain of APLP1 and APLP2, respectively, were inserted into pGBT9 to produce pGBT9hAPLP2 COOH and pGBT9hAPLP1 COOH . These constructs in pGBT9 vectors were used to examine the binding ability for human X11L (pGAD424#104) in the yeast two-hybrid system.
␤-Galactosidase activity in the yeast two-hybrid system was measured in a liquid assay using o-nitrophenylgalactopyranoside according to the manufacturer's protocol (CLONTECH Laboratories; catalog no. PT1265-1) and was expressed in Miller units.
Antibodies-The polyclonal anti-X11L amino-terminal domain antibody UT-29 was raised against a peptide, "Cys" plus containing the amino acid sequence between positions 207 and 223 of human X11L. Another polyclonal anti-X11L carboxyl-terminal domain antibody, UT-30, was raised against the peptide "Cys" plus containing the amino acid sequence between positions 735 and 749 of human X11L. These peptides were synthesized at Quality Controlled Biochemicals Inc. (Hopkinton, MA). UT-29 and UT-30 are specific to X11L (see "Results") and appear not to react with X11. These antibodies were affinity-purified using antigen coupled to SulfoLink gel (Pierce). Anti-APP polyclonal antibody UT-18 was prepared against APP695-(676 -695). The specificity was identical to that of another anti-APP polyclonal antibody, UT-421, which has been fully characterized (15, 23) . Anti-A␤ monoclonal antibody, 2D1, recognizes a human-specific epitope FRH-(600 -602), which lies between the ␤-and ␣-secretase sites (23); 25C was prepared against human APP695-(621-631) (A␤- (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) ). Anti-FLAG monoclonal antibody M2 (Eastman Kodak Co.) and anti-APP extracellular domain monoclonal antibody LN27 (Zymed Laboratories Inc., San Francisco, CA) were purchased.
Preparation of Proteins and in Vitro Interaction of Human X11L with APP-The cDNA clones encoding human X11L, the domain structures of human X11L, and the cytoplasmic domain of human APP695 were subcloned into pGEX-4T-1 (Amersham Pharmacia Biotech) to produce GST fusion protein. The recombinant plasmids were introduced into E. coli JM109. Production of the fusion protein was induced by culturing the recombinant E. coli strains in the presence of 1 mM isopropyl-␤-Dthiogalactopyranoside. Cells were lysed in phosphate-buffered saline (PBS; 140 mM NaCl and 10 mM sodium phosphate (pH 7.4)) by sonication, and the lysate was centrifuged at 10,000 ϫ g for 20 min at 4°C. The resulting supernatant was applied to a glutathione-Sepharose 4B (Amersham Pharmacia Biotech) column (1-ml bed volume), and proteins bound to the beads were recovered with an elution buffer consisting of 5 mM glutathione and 50 mM Tris-HCl (pH 7.4). Affinity-purified GST fusion proteins were dialyzed against a buffer consisting of 20 mM Tris-HCl (pH 7.5)/2 mM EDTA/1 mM dithiothreitol, and the purity of the protein was examined by staining with Coomassie Brilliant Blue R-250 following SDS-PAGE. To prepare the affinity beads coupled to the GST fusion protein, 2-4 nmol of GST fusion proteins were incubated with 100 l of glutathione-Sepharose 4B for 1 h at 4°C with rotation. The efficiency of coupling, almost greater than 95% under these conditions, was determined by examining the protein content of the uncoupled protein.
Whole cell extracts of 293 cells that expressed stably transfected APP695 cDNA (pcDNA3APP695) (23) , human X11L cDNA (pcDNA3-hX11L), and cDNA encoding the domain structures of human X11L were prepared by lysing cells in lysis buffer (PBS containing 10 mM CHAPS, 5 g/ml chymostatin, 5 g/ml leupeptin, 5 g/ml pepstatin A, 1 mM Na 3 VO 4 , and 1 mM NaF) for 1 h on ice, followed by centrifugation at 12,000 ϫ g for 10 min at 4°C. The resulting supernatant containing APP695 and protein constructs from human X11L were used for the binding assay.
The protein samples, which were adjusted to contain approximately 2-4 nmol of protein, were applied to a column (100-l bed volume) of glutathione-Sepharose beads bearing GST fusion protein or GST alone (control). The beads were washed with binding buffer three times, and the protein complex was eluted with elution buffer. Following SDS-PAGE, the proteins were analyzed by immunoblotting with the indicated antibodies and 125 I-Protein A (Amersham Pharmacia Biotech). Protein concentration was determined by the micro-Lowry method with bovine serum albumin as a standard (26) .
Co-immunoprecipitation-COS7 cells (ϳ1 ϫ 10 7 cells) were doubly transfected with 2 g of pcDNA3APP695 and 2 g of pcDNA3-hX11L in Lipofectamine (Life Technologies) for 18 h. After changing the medium, the cells were cultured for 48 h in Dulbecco's modified Eagle's medium containing 10% (v/v) heat-inactivated fetal bovine serum. The cells were harvested and lysed in 1 ml of lysis buffer (PBS containing 10 mM CHAPS, 5 g/ml chymostatin, 5 g/ml leupeptin, 5 g/ml pepstatin A, 1 mM Na 3 VO 4 , and 1 mM NaF) for 1 h on ice and centrifuged at 12,000 ϫ g for 10 min at 4°C. The affinity-purified polyclonal antibodies (50 g) UT-18 and UT-30 and monoclonal antibodies (50 g) 2D1 and 25C were added to the supernatant and incubated on ice for 1 h. Protein G-Sepharose beads were then added and incubated for 1 h at 4°C, and the samples were centrifuged. The pellets were washed with the lysis buffer three times, and proteins were eluted by boiling the pellet in SDS-sample buffer (23) . Proteins were then analyzed by SDS-PAGE (6% (w/v) polyacrylamide) and immunoblotted with the indicated antibodies, and immunocomplexes were revealed by ECL (Amersham Pharmacia Biotech).
Immunocytochemistry-293 cells that express stably transfected pcDNA3-hX11L were fixed for 20 min with 4% (w/v) paraformaldehyde in PBS (pH 7.4) containing 4% (w/v) sucrose, permeabilized with 0.2% (v/v) Triton X-100 for 5 min and blocked for 1 h in PBS containing 0.2% (v/v) goat serum. The same cells were double-stained with rhodamineconjugated Con A (Vector Laboratories, Inc., Burlingame, CA), which binds with high affinity to glycoproteins in the ER and cis-Golgi, or with rhodamine-conjugated WGA (Vector Laboratories), which binds with high affinity to glycoproteins in medial and trans-Golgi (27, 28) . In a separate study, 293 cells that express stably transfected pcDNA3-APP695 were further transfected with pcDNA3-hX11L transiently. The cells were incubated with anti-human X11L antibody UT-30 and anti-APP monoclonal antibody LN27 and then with fluorescein isothiocyanate-or rhodamine isothiocyanate-conjugated secondary antibody (Zymed Laboratories Inc., San Francisco, CA). The coverslips were mounted in immersion oil type B (R. P. Cargille Laboratories Inc., Cedar Grove, NJ), and the cells were viewed using a confocal laser scanning microscope, Bio-Rad MRC 600.
Western Blot Analysis of Mouse X11L from Adult Tissues-Tissues from adult ddY mice (4 -5 weeks) were homogenized and sonicated in a solution containing 50 mM Tris-HCl (pH 7.4), 1% (w/v) SDS, 2.7 M urea, 25 g/ml pepstatin A, 25 g/ml leupeptin, and 25 g/ml chymostatin. Samples were centrifuged (10,000 ϫ g, 10 min), the resulting supernatant (150 g of protein) was subjected to SDS-PAGE (7.5% (w/v) polyacrylamide), and proteins were electrophoretically transferred to a nitrocellulose membrane. The membrane was probed with UT-30 and 125 I-Protein A (Amersham Pharmacia Biotech). Radioactivity was analyzed by autoradiography.
Comprehensive Gene Mapping-The somatic cell hybrid Southern DNA membranes, BIOSMAP, were purchased from BIOS Laboratories (New Haven, CT). Southern hybridization was performed with a probe prepared from a template containing the insert from pcDNA3-hX11L with random oligonucleotides (High Prime DNA labeling kit; Boehringer Mannheim) and [␣-
32 P]dCTP (3000 Ci/mmol; NEN Life Science Products) according to the user guidelines.
Northern Analysis of Human X11L-Human multiple tissue Northern blots (catalog no. 7760-1) were purchased from CLONTECH Laboratories. Hybridizations were carried out using the standard procedure (29) . Radioactive probes with a specific activity equal to, or higher than, 1 ϫ 10 8 cpm/g were prepared from a template of human X11L cDNA coding for the amino acid sequence between positions 126 and 749 using [␣-32 P]dCTP (3000 Ci/mmol, NEN Life Science Products) and random oligonucleotides (High Prime DNA labeling kit; Boehringer Mannheim).
ELISA Analysis-The 293 cell line that expresses stably transfected pcDNA3APP695 (15, 23) was co-transfected with 10 g of pcDNA3-hX11L, which contained the cDNA sequence encoding the full-length form of human X11L (amino acid sequence 1-749), pcDNA3-N ϩ PI, which contained the cDNA encoding the amino-terminal region attached to the PI domains (amino acid sequence 1-555), pcDNA3-PI, which contained the cDNA encoding the PI domain (amino acid sequence 368 -555), or the control plasmid pcDNA3, which lacked a cDNA sequence (Invitrogen, Carlsbad, CA). The cells were supplied with fresh growth media 12 h after the start of transfection, and conditioned medium from cells (2 ϫ 10 6 cells) was collected 72 h after the medium change. A␤40 and A␤42 were quantified with sandwich ELISA using three types of A␤-specific monoclonal antibodies as described previously (15, 23) . Briefly, wells were coated with the A␤40 (4D1) or A␤42 (4D8) end-specific monoclonal antibodies (0.3 g of IgG in PBS), washed with PBS containing 0.05% (v/v) Tween 20 (washing buffer), blocked with bovine serum albumin (3% (w/v) in PBS), and washed with washing buffer, and then a sample (100 l) diluted suitably with washing buffer containing 1% (w/v) bovine serum albumin (dilution buffer) was incubated together with a standard dose of synthetic A␤-(1-40) and A␤-(1-42) peptides (synthesized using solid phase t-BOC (N-tert-butyloxycarbonyl)-chemistry by Dr. James I. Elliott at the W. M. Keck Foundation Biotechnology Resource Laboratory, Yale University). After washing, wells were treated with biotinized 2D1 (12. 5 ng in dilution buffer), washed, and incubated with 100 l of a streptavidin-horseradish peroxidase complex (1:2000 dilution; Amersham Pharmacia Biotech catalog no. RPN1051). The plates (96 wells) were washed further, 100 l of 2,2Ј-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid solution (KPL 5062-01, Kirkegaard & Perry Laboratories, Gaithersburg MD) was added to the wells, and incubation was continued at room temperature. The reaction was stopped by adding 100 l of 1% (w/v) SDS, and the absorbance at 405 nm was measured.
RESULTS

Molecular Cloning of a cDNA Encoding Human X11L Protein: Primary Structure and Chromosome Location-
The short cytoplasmic domain of APP is the sole region exposed to the cytoplasm and contains several functional amino acid motifs that regulate the metabolism of APP (13-15, 30, 31) . Therefore, the isolation and characterization of proteins which interact with APP COOH are important for our understanding the physiological function and metabolism of APP. Approximately 10 6 independent clones from an adult human brain cDNA library were screened by the yeast two-hybrid system with a "bait" vector containing the cDNA encoding the 47-amino acid APP COOH region, pGBT9APP COOH . Ultimately, 125 clones were isolated as positive for nutrient (His) selection and ␤-galactosidase activity. The nucleotide sequences of all the positive candidates were determined. Out of the 125 clones, 88 encoded the amino acid sequence of Fe65 (17) or Fe65-like (18) proteins, which have previously been reported to be APP-binding proteins. Nucleotide sequences of the other four clones revealed a novel protein sequence with higher homology to mouse X11 than to human X11 (25) . Other sequences were nonsense clones, which were not thought to encode significant proteins. One of the four cDNA clones, pGAD424#104, contained an open reading frame coding for a potentially novel protein of 624 amino acids, as shown in amino acid positions 126 -749 of human X11L (Fig. 1a) , and contained a 3Ј-untranslated and poly(A) ϩ sequence. To identify the 5Ј nucleotide sequence of this clone, we performed the RACE procedure using poly(A) ϩ RNA from human adult brain and the indicated primer (underlined in Fig. 1a) , which corresponds to amino acid positions 130 -135. An approximately 620-nucleotide sequence including the missing 260 base pairs of the 5Ј-untranslated region was determined, and the whole amino acid sequence of this clone was deduced (Fig. 1a) . This protein showed high homology to the partial amino acid sequence of mouse X11 rather than to human X11. Because the amino-terminal sequence of mouse X11 has not been reported (25), we also determined the 5Ј nucleotide sequence of mouse X11 by the RACE procedure using poly(A) ϩ RNA from mouse adult brain and the indicated primer (underlined in Fig. 1a) , which corresponds to amino acids 80 -85. The entire amino acid sequence of the aminoterminal part of mouse X11 was deduced, and the sequence was used to look for homology between the three related proteins (Fig. 1) .
The human X11L cDNA encoded a protein consisting of 749 amino acids and presented 55.2% amino acid homology to the partially known amino acid sequence of human X11 and 90.2% homology to the complete sequence of mouse X11, which consists of 748 amino acids. Thus, we designated this protein as human X11-like protein (human X11L), whose partial sequence consisting of 188 amino acids comprising the PI domain has already been reported (22) . Furthermore, mouse X11 (25) is thought to be a homologue of human X11L because it possesses higher homology to human X11L than to human X11. Thus, we surmise that the mouse counterpart of the human X11 gene has not yet been identified. Therefore, we have referred to mouse X11 as mouse X11L in the present paper (Fig. 1a) .
The human X11L protein contains a PI domain (Fig. 1a , yellow box) and two PDZ domains (Fig. 1a, blue boxes) (the repeated sequences of the brain-specific protein PSD-95, Drosophila septate junction protein disks-large, and the epithelial tight-junction protein ZO1) (32) in its carboxyl-terminal domain, as does human X11 (Fig. 1b) . The PI domain (amino acid positions 368 -555, 82.4% homology) as well as the region that lies on the carboxyl-terminal side (amino acid positions 556 -749, 85.6% homology) of the PI domain, but not the aminoterminal domain (amino acid positions 1-367, 20.6% homology), are highly conserved between the human X11L and X11 proteins (Fig. 1) .
The chromosomal location of the human X11 gene has been fully characterized (21) . The gene is located on 9q13-q21 within 0.7 centimorgans of the D9S5 and D9S15 loci. We identified the chromosome on which human X11L gene is located using a comprehensive gene mapping procedure with the somatic cell hybrid Southern DNA membrane as described under "Experimental Procedures". Southern hybridization with a probe of human X11L whole cDNA, pcDNA3-hX11L, indicated that the human X11L gene is located on human chromosome 15 (data not shown), a location that is distinct from that of the X11 gene located on chromosome 9.
Binding of Human X11L Protein to APP-X11 and Fe65 have been shown to interact with the YENPTY (APP-(682-687) of APP695 isoform) motif of APP COOH through their PI domains. In contrast to the interaction involving the Shc PI domain, the interaction is independent of APP tyrosine phosphorylation (20, 33) . To characterize the binding of X11L to APP, we performed a yeast two-hybrid study using a combination of the cDNA encoding the domain sequence derived from human X11L in pGAD424 and the cDNA of APPCOOH, pGBT9APP COOH (Fig. 2) , and another combination of the cDNA coding for almost the whole length of human X11L, pGAD424#104, and the cDNA of APP COOH truncated internally in pGBT9 (Fig. 3a) . The ␤-galactosidase activities (Miller units) of both combinations were measured and compared (Figs. 2 and  3a) . The PI domain (pGAD424#PI, containing the cDNA coding for amino acids 368 -555) was essential for binding to APP and gave almost the same activity as that of the plasmid coding for the full-length human X11L, pGAD424#104. We found that when the PI domain was attached to the amino-terminal domain (pGAD424#1, containing the cDNA coding for amino acids 126 -555) the activity was enhanced (2-fold). However, when the PI domain was attached to the carboxyl-terminal domain (pGAD424#4, containing the cDNA coding for amino acids 368 -749) APP binding ability was markedly suppressed (Fig. 2) . The amino-terminal (pGAD424#6 containing cDNA coding for amino acids 126 -367) and carboxyl-terminal (pGAD424#7 containing cDNA coding for amino acids 556 -749) domains alone were negative for both ␤-galactosidase activity and His nutrient selection and had no ability by themselves to bind to APP COOH . A cDNA construct coding for amino acids 1-125 gave a nonspecific and constitutive positive signal in the nutrient and ␤-galactosidase assays of the yeast twohybrid system, which indicates that this region contains an artificial trans-activator sequence of Gal4-mediated transcription. Therefore, we deleted this region from the cDNA constructs for the two-hybrid assays.
When the binding site of the cytoplasmic domain of APP was examined (Fig. 3a) , we found that a cDNA, pGBT9APP-695⌬681-690, encoding the cytoplasmic domain with a deletion of amino acids 681-690 containing the NPTY sequence had lost binding ability for human X11L. Another construct, pGBT9APP695⌬669 -680, with a deletion of the amino-terminal 15 amino acid residues to the NPTY motif retained binding ability, but the binding was slightly weaker compared with that of the whole sequence (wild type). The results indicate that the sequence containing the NPTY motif of APP is essential for association with human X11L as well as with X11 and Fe65/ Fe65-like (17) (18) (19) (20) .
APP is a member of a gene family that includes APLP1 (34) and APLP2 (35) . The amino acid sequences of these proteins are highly conserved, especially within their cytoplasmic domains. The binding ability of human X11L to the cytoplasmic domain of APLPs was examined using the yeast two-hybrid system (Fig. 3b) . When pGAD424#104 was co-transfected with pGBT9APLP2 COOH consisting of the cDNA encoding the 47-amino acid human APLP2 cytoplasmic domain (Fig. 3b,  APLP2 ), or pGBT9APLP1 COOH consisting of the cDNA encoding the 46-amino acid human APLP1 cytoplasmic domain (Fig.  3b, APLP1 ) in yeast, equal or greater ␤-galactosidase activities were observed than for APP COOH (Fig. 3b, APP) . These results indicate that human X11L associates with APP family proteins, APP, APLP1, and APLP2, all of which contain NPXY motifs. The control vector, pGBT9, which did not contain cDNA gave no ␤-galactosidase activity (Fig. 3b, control) .
Interaction of APP with Human X11L Using GST Fusion Proteins in Vitro-The protein-protein interaction of human X11L with APP was examined in vitro using GST-human X11-like fusion protein (GST-hX11L) and human APP695 (Fig. 4, a  and b) . Glutathione-Sepharose beads bearing GST fusion proteins, whose constructs are shown in Fig. 4d , were incubated with the lysate of 293 cells that were stably transfected with pcDNA3APP695 containing human APP695 cDNA. The beads were washed with binding buffer three times, and protein complexes were eluted with PBS containing 5 mM reduced glutathione. Following SDS-PAGE, the proteins were analyzed by immunoblotting with anti-APP antibody UT-18 plus 125 IProtein A (arrows in Fig. 4, a and b (longer exposure of a) , indicate mature (m, upper) and immature (im, lower) APP695 isoforms). APP was found to associate with the PI domain (PI, amino acid positions 368 -555) as well as with full-length human X11L (human X11L). The PI domain attached to the amino-terminal domain (N ϩ PI; amino acid positions 1-555) enhanced binding to APP, and the PI domain attached to the carboxyl-terminal domain (PI ϩ C, amino acid positions 368 -749) suppressed binding to APP. The amino-terminal (N, amino acid positions 1-367) and carboxyl-terminal (C, amino acid positions 556 -749) domains alone did not bind to APP. The results of these assays corroborate the results obtained using the yeast two-hybrid assay (Fig. 2) . In addition, the results suggested that the amino-and/or carboxyl-terminal domains may be regulatory element(s) of PI domain binding to APP.
In order to confirm the protein-protein interaction of human X11L with APP COOH , the studies described in Fig. 4 , a and b, were performed again but with the difference that glutathioneSepharose beads bearing GST-APP COOH fusion protein (APP COOH ) were incubated with the cell lysates from 293 cells that expressed stably transfected pcDNA3-hX11L (human X11L), pcDNA3-N ϩ PI (N ϩ PI), or pcDNA3-N (N) (Fig. 4c) . These cell lysates contain the respective protein constructs as shown in "crude" of Fig. 4c . The beads were washed with binding buffer three times, and protein complexes were eluted with PBS containing 5 mM reduced glutathione. Following SDS-PAGE, the proteins were analyzed by immunoblotting with anti-X11L antibody UT-29 plus 125 I-Protein A. Full-length human X11L was found to associate with GST-APP COOH fusion protein on the beads (human X11L). The PI domain fused to the amino-terminal domain (amino acid positions 1-555) associated strongly with the GST-APP COOH fusion protein on the beads (N ϩ PI). However, the amino-terminal domain (amino acid positions 1-367) alone did not associate with GST-APP COOH fusion protein (N). The beads carrying GST peptide alone (GST) did not present any appreciable ability to associate with human X11L or its domain structure proteins. We have not studied binding of the PI domain (PI) alone, nor the PI domain fused to the carboxyl-terminal domain (PI ϩ C), nor the carboxyl-terminal domain alone (C), because we had no PIspecific antibody and could not establish 293 cell lines stably transfected with pcDNA3-PI ϩ C or pcDNA3-C. However, the results broadly confirmed the data presented in Fig. 4, a and b , and, especially, proved that deletion of the human X11L carboxyl-terminal domain enhances the binding of human X11L to APP COOH .
Specificity of the Anti-X11L Antibody and Brain-specific Expression of X11L-Antibodies raised against sequences in the amino-terminal (UT-29) and the carboxyl-terminal (UT-30) regions of the PI domain were examined for their specificity. Human X11L tagged with the FLAG peptide on its carboxylterminal side (FLAG-hX11L) was prepared. From the lysates of 293 cells, which were stably transfected with FLAG-hX11L cDNA (pcDNA3-FLAG-hX11L), proteins were immunoprecipitated (IP) with anti-FLAG (M2), UT-29, or UT-30 antibodies, separated by SDS-PAGE, transferred to nitrocellulose membrane, and probed (WB) with the indicated antibodies (Fig. 5a) . Because a ϳ135-kDa protein (arrow) was detected with all three types of antibodies, we designated the ϳ135-kDa protein as FLAG-hX11L. When crude cell lysates were probed with these three antibodies, the ϳ135-kDa protein was also specifically detected (Fig. 5a, crude) . Preincubation of antibodies with the corresponding antigen peptides (10 M) resulted in the failure of these antibodies to recognize the ϳ135-kDa protein (data not shown). The results demonstrate that both UT-29 and UT-30 antibodies are highly specific for human X11L and that they are potentially useful for detecting endogenous X11L. Endogenous X11L was also analyzed (Fig. 5b) ; mouse X11L was immunoprecipitated (IP) from mouse brain lysate with UT-29 or UT-30. The immunoprecipitate was analyzed by Western blot (WB) with UT-29 or UT-30. When crude brain lysate (Fig.  5b, crude) was probed directly, the ϳ135-kDa protein (arrow) was also detected by both UT-29 and UT-30. The efficiency of immunoprecipitation of mouse X11L by UT-30 is much higher than that of UT-29 (compare left part with middle part of Fig.  5b) , although UT-29 and UT-30 immunoprecipitate human X11L equally well as shown in Fig. 5a . The amino acid se- quence of the region used to raise the UT-29 antibody was not identical between human and mouse (15/17 amino acid identity) X11L, although that used to raise UT-30 was identical (15/15 amino acid identity). Since UT-29 was raised against the human sequence, the antibody may not be as effective in recognizing the mouse protein, especially in immunoprecipitation. The molecular size of X11L deduced from the cDNA is 82.5 kDa, which is much smaller than 135 kDa, the value determined by SDS-PAGE. One explanation for this discrepancy could be that X11L is subject to modifications such as glycosylation. However, this does not seem plausible, because the GST-hX11L fusion synthesized in E. coli also migrated as a 160-kDa protein during SDS-PAGE, and a ϳ135-kDa protein after the removal of the GST peptide by digestion with thrombin (data not shown). The most plausible explanation is that X11L adopts a secondary structure that results in anomalous migration during SDS-PAGE. Immunoprecipitates from the lysate (approximately 1 mg of protein) were subjected to SDS-PAGE (6% (w/v) polyacrylamide), proteins were transferred to a nitrocellulose membrane, and the membrane was probed (WB) with M2, UT-29, or UT-30 antibodies. Immunocomplexes were detected by incubation with anti-mouse IgG peroxidase or anti-rabbit IgG peroxidase followed by ECL. The ϳ135-kDa protein indicated with an arrow is FLAG-hX11L. b, mouse brain lysate (crude, 100 g of protein) was subject to immunoprecipitation (IP) using UT-29 and UT-30 antibodies. Immunoprecipitates from the lysate (approximately 1 mg of protein) were probed (WB) with UT-29 and UT-30 antibodies, and immunocomplexes were detected by ECL with anti-rabbit IgG following SDS-PAGE (6% (w/v) polyacrylamide) and transfer of proteins to a nitrocellulose membrane. PC, sample was subjected to preclearing with Protein A-Sepharose prior to the addition of the antibody; w/o PC, sample was immunoprecipitated without preclearing; Comp, sample was immunoprecipitated with indicated antibodies in the presence of antigen peptide (10 M). The ϳ135-kDa protein indicated with an arrow is mouse X11L. UT-29 does not react with mouse X11L in immunoprecipitation (see text). Numbers are the molecular masses (kDa) of the protein standards. c, mouse tissues lysate (150 g of protein) was subject to SDS-PAGE (6% (w/v) polyacrylamide), and proteins were transferred to a nitrocellulose membrane. The membrane was probed with UT-30 and 125 I-Protein A and then analyzed by autoradiography. An arrow indicates the position of mouse X11L.
It has been reported that human X11 is expressed dominantly (21) but not specifically 2 in brain tissues. However, the expression patterns of human and mouse X11L have not been examined, although both X11 and X11L proteins are similar with respect to structure and APP binding. The expression of mouse X11L in various tissues was examined (Fig. 5c) . Protein extracts (150 g of protein) from various adult mouse tissues were analyzed by Western blot with UT-30 antibody. A ϳ135-kDa mouse X11L protein (Fig. 5c, arrow) was detected specifically in brain but not in other nonneuronal tissues such as heart, lung, liver, testis, spleen, thymus, or kidney. The results indicated brain-specific expression of X11L protein.
We further performed Northern blot analysis using a probe derived from human X11L cDNA as described under "Experimental Procedures." This Northern blot analysis showed a strong 4.4-kb and a comparatively weak 4.0-kb message in brain tissue but not in the other nonneuronal tissues examined (Fig. 6a) . The actin gene was found to exist in all tissues (Fig.  6b) . The size of the mRNA is in good agreement with the size of human X11L cDNA and clearly differs from the mRNA size of human X11 (21) . Thus, we concluded that the major 4.4-kb product is the mRNA that encodes human X11L. The minor 4.0-kb product may be a truncated mRNA or a minor product derived from alternative splicing of human X11L gene transcripts. These results demonstrate that X11L gene is specifically expressed in neuronal tissue and suggests that the protein product may play a role in neuron-specific function(s) through association with APP.
In Vivo Interaction of Human X11L with APP-To examine whether human X11L and APP interacted in cells, co-immunoprecipitation experiments were performed. COS7 cells that transiently express human X11L and APP695 were lysed in the presence of 10 mM CHAPS. The detergent-soluble fraction was subjected to immunoprecipitation (IP) using affinity-purified UT-30 or anti-APP extracellular domain monoclonal antibodies 2D1 and 25C (Fig. 7) . The same quantity of normal rabbit or mouse IgG was used as a control. The immunoprecipitates were analyzed by Western blot (WB) using UT-18 (Fig. 7a) or UT-30 (Fig. 7b) antibody. APP was detected in the sample immunoprecipitated with UT-30 (Fig. 7a) . Human X11L was detected in the sample immunoprecipitated with 2D1 and 25C (Fig. 7b) . APP and human X11L could not be detected in the sample immunoprecipitated using normal rabbit or mouse IgG, indicating that the co-immunoprecipitation of APP and human X11L was specific. The result suggests that APP and X11L interact in mammalian cells.
Intracellular Distribution of Human X11L and APP-The intracellular distribution of human X11L was examined by an immunocytochemical study using 293 cells stably expressing human X11L protein. The 293 cells that express stably transfected pcDNA3-human X11L were double-stained with UT-30 and WGA (medial-plus trans-Golgi marker) or ConA (ER plus cis-Golgi marker) (23, 27, 28) to analyze the intracellular distribution of human X11L (Fig. 8, a and b) . In a separate study, the 293 cells stably transfected with pcDNA3-APP695 and transiently transfected with pcDNA3-hX11L were doublestained with UT-30 and LN-27 antibodies to analyze for codistribution of human X11L and APP (Fig. 8c) . The cells were then observed under a confocal laser scanning microscope. We found that the staining of human X11L with UT-30 (green in Fig. 8, a and b) partially co-localized with the staining obtained using WGA (red in Fig. 8a ) and ConA (red in Fig. 8b ). It is also clear that UT-30 did not stain the plasma membrane. These results show that X11L protein is present in the cytoplasm and to a lesser extent in the ER and Golgi apparatus as shown by the yellow color (hX11L/WGA in Fig. 8a and hX11L/ConA in Fig. 8b ). LN27 stained the Golgi apparatus strongly (red in Fig.  8c ), which agrees with a previous report on the cellular distribution of APP (23) . Taken together, these observations indicate that APP (red) may be colocalized with human X11L (green) mostly in the Golgi apparatus (hX11L/APP in Fig. 8c ), although the majority of human XIIL was localized in the cytoplasm. The antibody that had been preadsorbed to antigen did not show any staining (data not shown).
The distribution of X11L was confirmed by a biochemical study. Mouse brain homogenate was fractionated into nuclear, membrane, and cytosolic fractions and then analyzed by immunoblot analysis with the UT-30 antibody. Most of the mouse X11L protein was detected in the cytosolic fraction with a 2 S. Tomita and T. Suzuki, unpublished observation. smaller quantity of mouse X11L being also detected in crude membrane fractions consisting of the plasma membrane, ER, and Golgi apparatus membranes. This indicates that X11L may be attached to these membranes through association with APP (data not shown). The results of the immunocytochemical (Fig. 8 ) and biochemical studies indicate that X11L is most likely a cytosolic protein with a tendency to co-distribute with APP.
Role of X11L Protein in APP Processing: Generation of ␤-Amyloid Peptides-To examine whether X11L regulates APP processing through its interaction with APP COOH , the effect of X11L on the generation of both A␤40 and A␤42 peptides was examined (Fig. 9) . The 293 cells that stably expressed human APP695 (15, 23) were co-transfected transiently with the cDNA encoding full-length human X11L, N ϩ PI (amino acid positions 1-555), PI (amino acid positions 369 -555), or vector alone (control) (see Fig. 4 for protein construction) . We have already demonstrated that these three constructs, full-length human X11L, N ϩ PI, and PI, can associate with APP COOH (Figs. 2 and  4) . At 72 h after supplementation of the cells with fresh medium following transfection, the conditioned media were collected, and the levels of A␤40 and A␤42 were quantified by sandwich ELISA (15, 23) . The relative ratios of the levels of A␤ to the control level (reference value set to 1.0) were determined. The full-length human X11L construct decreased the level of A␤40 secretion but not that of A␤42. The levels of A␤40 produced from cells expressing N ϩ PI or PI domains did not change compared with the levels produced by control cells, despite the fact that the N ϩ PI and PI domain have binding ability for APP COOH (Fig. 4) . The secretion level of A␤42 was not altered remarkably by co-transfection with human X11L or its domain structures (Fig. 9b) . These results suggest that human X11L functions to modulate APP processing. The constructs N ϩ PI and PI did not have this modulator function, indicating that the carboxyl-terminal region is important for APP processing. The study indicates that the PDZ domains in the carboxyl-terminal domain of human X11L play an important role in APP processing. Furthermore, the results suggest that regulation of A␤42 production may differ from that of A␤40. DISCUSSION APP was identified as a causative factor in the pathogenesis of AD (1, (5) (6) (7) (8) (9) (10) (11) . Several mutations of APP and other AD-related genes have been found in familial AD, and it has been reported that these mutations contribute to the pathogenesis of familial AD (reviewed in Refs. 36 and 37). However, familial AD represents only a small minority of AD cases. The majority of AD cases are of the sporadic type, whose patients are not thought to carry the mutation. Therefore, elucidation of the physiological function(s) and metabolism of APP is critical for our understanding of the pathogenesis of sporadic type AD. The cytoplasmic domain of APP, or APP COOH , which is highly conserved phylogenetically in vertebrates (38) , contains signals for APP metabolism (13) (14) (15) and is thought to contain the amino acid sequence essential for the transduction of signals from an extracellular ligand that remains to be identified (reviewed in Ref. 16 ). Consequently, research based on the identification and isolation of factors that interact with APP COOH has been pursued (17-20, 39, 40) . In the present paper, we isolated a cDNA encoding a novel protein, human X11L, as a protein that binds to APP COOH . This human X11L possesses 55.2% homology to human X11, which has been identified as a gene in the region of the Friedreich ataxia locus (21), a degenerative disorder involving both the central and peripheral nervous system (41) . Although a partial amino acid sequence consisting of 165 amino acids in the PI domain of X11L has been identified as the APP binding motif (22) and the interaction between the PI domain of X11 and a sequence containing the NPTY motif of APP COOH has been fully analyzed (20, 33) , the biological function of these proteins has not been determined. Because the amino acid homology between the PI domains from human X11 and human X11L is very high (82.9%), the architecture and APP COOH recognition mechanism of the PI domains from both proteins may be similar. In the present study, we demonstrate that the interaction of human X11L with AP-P COOH is enhanced by deletion of the carboxyl-terminal domain and suppressed by deletion of the amino-terminal domain (Figs. 2 and 4) . One possible explanation for these results is that both domains function as regulatory elements of PI domain binding to APP COOH , possibly indicating that the aminoterminal domain contains an "enhancer" sequence and the carboxyl-terminal domain contains a "suppressor" sequence for PI domain binding to APP COOH . The deletion of the amino-or carboxyl-terminal domain may alter the conformation of the PI domain, and this may affect the binding affinity to APP COOH . Although these deleted constructs of human X11L are not physiological products, in vivo, proteins that can interact with the amino-and/or the carboxyl-terminal domains of X11L may regulate APP binding to the PI domain by inducing conformational changes in human X11L. We propose a possible hypothesis for the regulation of X11L binding to APP COOH (Fig. 10) . In cells, X11L exists in a free form and shows a weak affinity for APP COOH (Fig. 10a) . When an unidentified "factor X" binds to the amino-terminal domain of X11L, the PI domain adopts an altered conformation and acquires strong binding affinity for APP COOH (Fig. 10b) . The construct deleted for the carboxylterminal domain (N ϩ PI construct) may mimic this strong binding state of X11L (Fig. 10d) . Then the PDZ domain(s) of the stable X11L⅐APP complex, associate with another factor, "factor Y," resulting in the suppression of A␤40 production (Fig.  10c) . We have already isolated several novel proteins that bind to the amino-terminal domain. 3 One of these proteins may be "factor X."
When the ability of full-length human X11L, N ϩ PI, or PI constructs on A␤ production was examined in cells, only fulllength human X11L reduced the secretion of A␤40. This result agrees well with our hypothesis. The constructs deleted for the carboxyl-terminal domain (N ϩPI construct), which preserves human X11L binding ability for APP COOH 
FIG. 10.
Possible role of X11L in APP processing. a, the X11L protein binds to the APP COOH domain weakly via its PI domain ("weak associated state"). b, when factor X binds to the amino-terminal domain, the conformation of X11L changes and the X11L⅐factor X complex binds to APP COOH with high affinity ("strong associated state"). c, when the PDZ domain(s) in the carboxyl-terminal domain of the X11L are in a strong associated state, another "factor Y" binds. This binding may be essential for suppression of A␤40 secretion. d, A construct with a deletion of the carboxyl-terminal domain (N ϩ PI) can bind to APP COOH with high affinity. In this case, the conformation of N ϩ PI is thought to mimic the strong associated state. This construct does not suppress the secretion of A␤40, because it lacks the carboxyl-terminal domain. e, the construct containing the PI domain alone can bind to APP COOH perhaps without any regulation. f, the construct with a deletion of the aminoterminal domain (PI ϩ C) cannot bind to APP COOH because of the suppressor effect of the carboxyl-terminal domain and the missing amino-terminal domain. M, membrane; A␤, ␤-amyloid; N, amino-terminal domain of X11L; PI, PI domain of X11L; C, carboxyl-terminal domain of X11L; X, a putative factor X, which binds to the aminoterminal domain of X11L; Y, a putative factor Y, which binds to the carboxyl-terminal domain of X11L.
would also appear to support our hypothesis. Neither the PI domain alone nor the N ϩ PI domain is sufficient to regulate APP metabolism if it binds to APP COOH with higher affinity (Fig. 10, d and e) . The human X11L construct lacking the amino-terminal domain (PI ϩ C) loses its binding affinity for APP COOH (Fig. 10f) . The carboxyl-terminal domain containing the PDZ domains may be essential for the regulation of A␤40 production. We have not examined how the PDZ domains function to regulate A␤40 production in detail. However, it has been well established that the PDZ domain interacts with other proteins (32, 42, 43) . Fig. 10 proposes that an association of an unidentified "factor Y" to the PDZ domain(s) may be necessary to regulate APP processing.
APP COOH is not subject to tyrosine phosphorylation, 4 and it is believed that the mode of binding of X11 and X11L to a sequence containing the NPXY motif in APP COOH is a phosphotyrosine-independent interaction such as in the case of Shc phosphotyrosine binding/PI (44) . However, APP COOH contains other phosphorylation sites (45) (46) (47) . One of these, Thr 668 , is located at position 16 in the amino-terminal region of the NPTY motif and is phosphorylated in brain tissue (48) . Furthermore, we have found that Thr 668 phosphorylation of mature APP (mAPP, N-and O-glycosylated form) is neuron-specific, 5 although Thr 668 phosphorylation of immature APP (N-glycosylated form) is observed in nonneuronal cells during the mitotic phase of cell division (47) (48) (49) . Therefore, we examined the effect of phosphorylation of APP at Thr 668 on the interaction between X11L and APP COOH . A single amino acid mutation that changed this threonine to alanine or glutamic acid did not alter the binding of APP to the PI domain of human X11L. 2 This result indicates that the association of X11L with APP COOH is not dependent on the phosphorylation of APP.
Because proteins containing the PDZ domain are known to play a role in the clustering of membrane receptors and channels (50) and because the expression of X11L is brain-specific, X11L may also play an important role in neuronal function(s) through its association with APP. While we were preparing this manuscript, we found that a cDNA similar to human X11L could be isolated from rat as a protein interacting with Munc 18, Mint (51) . Munc 18 is thought to be a protein required for synaptic vesicle exocytosis. Mint-1 and Mint-2 seem to be rat homologues of human X11 and X11L, respectively. The Munc 18 binding domain is located in the amino-terminal region of the PI domain of X11L/Mint-2, and a complex consisting of Mint and Munc18 is thought to play a role in the docking of synaptic vesicles to the active zone (51) . This observation suggests that APP may play an important role in neurotransmitter release at nerve terminals or that Mint-2 may regulate the binding ability of X11L to APP. Since we have demonstrated that mAPP localizes in the nerve terminals of cholinergic neurons (38) , one may hypothesize that APP interacts with the exocytotic machinery proteins of synaptic vesicles via X11L/ Mint-2. Since cholinergic neurotransmission is thought to be involved in learning and memory processes (52) and loss of function in cholinergic neurotransmission has been observed in senile dementia of AD (53) , further characterization of X11L should increase our understanding of the physiological function of APP and the pathogenesis of sporadic type AD.
Furthermore, while this manuscript was being reviewed, a report appeared showing that X11 has an inhibitory effect on both A␤40 and A␤42 secretion using a double transient expression system with APP and X11 cDNAs (54) . The X11 and X11L proteins may regulate APP metabolism in a different fashion due to differences in their amino-terminal domain structures.
